Crockett Thomas Andrew 4
4 · KalVista Pharmaceuticals, Inc. · Filed Feb 16, 2024
Insider Transaction Report
Form 4
Crockett Thomas Andrew
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2024-02-14$15.01/sh−58,356$875,883→ 181,676 total
Footnotes (1)
- [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of performance stock units. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.